Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Early Detection of Complications During Immunotherapy for Haematological Malignancy

NCT: NCT06377059 · RECRUITING

NCT IDNCT06377059
StatusRECRUITING
Start Date2024-12-02
Completion2027-07-01

Brief Summary

Aims * To identify patients that should remain admitted in hospital for more intense surveillance because of high risk for development of clinical complications * Expand the understanding of the interactions between physiology and immunology for the design of future projects and general knowledge Hypothesis Development of a risk model based on a combination of physiological and immunological parameters can contribute to early detection of patients at risk for clinical complications after anti-cancer treatment.

Frequently Asked Questions

What is Early Detection of Complications During Immunotherapy for Haematological Malignancy?

Early Detection of Complications During Immunotherapy for Haematological Malignancy is a clinical trial registered under NCT06377059. Current status: RECRUITING.

What is the status of NCT06377059?

The current status of NCT06377059 (Early Detection of Complications During Immunotherapy for Haematological Malignancy) is: RECRUITING.

When did Early Detection of Complications During Immunotherapy for Haematological Malignancy start?

Early Detection of Complications During Immunotherapy for Haematological Malignancy started on 2024-12-02.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.